Phase I clinical trial evaluates the safety of IL-15-activated CD56+ cell infusion in high-risk acute myeloid leukemia, suggesting potential for future studies.
We identified a feasible method to activate CD56⁺ cells and evaluate the safety of their infusion in patients. Despite the value of activating CD56⁺ cells with IL-15, further studies with larger sample sizes are needed to confirm and validate the current hypothesi (registration number: IRCT20230801058996N2).
No takes yet. Share an insight, caveat, or question.
Eskandarian et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: